{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T06:20:22Z","timestamp":1788848422352,"version":"build-2803163510"},"reference-count":37,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,5,15]],"date-time":"2019-05-15T00:00:00Z","timestamp":1557878400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Medigen Vaccine Biologics Corporation"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Microbiology, Immunology and Infection"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.jmii.2019.03.009","type":"journal-article","created":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T21:04:32Z","timestamp":1558127072000},"page":"685-692","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["The safety and immunogenicity of a cell-derived adjuvanted H5N1 vaccine \u2013 A phase I randomized clinical trial"],"prefix":"10.1016","volume":"52","author":[{"given":"Aristine","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szu-Min","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Ching","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Han","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erh-Fang","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiang-Chi","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Wan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuan-Lang","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley","family":"Shi-Chung Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan-Chwen","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jmii.2019.03.009_bib1","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s12275-017-7062-7","article-title":"H5 influenza, a global update","volume":"55","author":"Harfoot","year":"2017","journal-title":"J Microbiol"},{"issue":"2","key":"10.1016\/j.jmii.2019.03.009_bib2","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1128\/CMR.00037-06","article-title":"Avian influenza virus (H5N1): a threat to human health","volume":"20","author":"Peiris","year":"2007","journal-title":"Clin Microbiol Rev"},{"issue":"4","key":"10.1016\/j.jmii.2019.03.009_bib3","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1586\/erv.09.15","article-title":"Current status and progress of prepandemic and pandemic influenza vaccine development","volume":"8","author":"Leroux-Roels","year":"2009","journal-title":"Expert Rev Vaccines"},{"issue":"7","key":"10.1016\/j.jmii.2019.03.009_bib4","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1111\/resp.13114","article-title":"A clinical approach to the threat of emerging influenza viruses in the Asia-Pacific region","volume":"22","author":"Hui","year":"2017","journal-title":"Respirology"},{"issue":"14","key":"10.1016\/j.jmii.2019.03.009_bib5","doi-asserted-by":"crossref","first-page":"7529","DOI":"10.1128\/JVI.00327-07","article-title":"Characterization of low-pathogenic H5 subtype influenza viruses from Eurasia: implications for the origin of highly pathogenic H5N1 viruses","volume":"81","author":"Duan","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.jmii.2019.03.009_bib6","series-title":"Cumulative number of confirmed human cases of avian influenza A(H5N1) reported to WHO","author":"World Health Organization","year":"2018"},{"issue":"9887","key":"10.1016\/j.jmii.2019.03.009_bib7","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0140-6736(13)61171-X","article-title":"Comparative epidemiology of human infections with avian influenza A H7N9 and H5N1 viruses in China: a population-based study of laboratory-confirmed cases","volume":"382","author":"Cowling","year":"2013","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.jmii.2019.03.009_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0161925","article-title":"Differences in the epidemiology of childhood infections with avian influenza a H7N9 and H5N1 viruses","volume":"11","author":"Sha","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jmii.2019.03.009_bib9","series-title":"Manual for the laboratory diagnosis and virological surveillance of influenza","author":"World Health Organization","year":"2011"},{"issue":"13","key":"10.1016\/j.jmii.2019.03.009_bib10","doi-asserted-by":"crossref","first-page":"4620","DOI":"10.1073\/pnas.0308001101","article-title":"Human and avian influenza viruses target different cell types in cultures of human airway epithelium","volume":"101","author":"Matrosovich","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.jmii.2019.03.009_bib11","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1080\/21645515.2016.1263410","article-title":"Randomized, double-blind, multi-center, phase III clinical trial to evaluate the immunogenicity and safety of MG1109 (egg-based pre-pandemic influenza A\/H5N1 vaccine) in healthy adults","volume":"13","author":"Song","year":"2017","journal-title":"Hum Vaccines Immunother"},{"issue":"24","key":"10.1016\/j.jmii.2019.03.009_bib12","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1016\/j.vaccine.2017.04.029","article-title":"A systematic review and meta-analysis of cross-reactivity of antibodies induced by oil-in-water emulsion adjuvanted influenza H5N1 virus monovalent vaccines","volume":"35","author":"Chada","year":"2017","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.jmii.2019.03.009_bib13","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1159\/000453150","article-title":"Immunogenicity and safety of pandemic influenza H5N1 vaccines in healthy adults through meta-analysis","volume":"40","author":"Guo","year":"2016","journal-title":"Cell Physiol Biochem"},{"issue":"6","key":"10.1016\/j.jmii.2019.03.009_bib14","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jmii.2012.08.002","article-title":"The Madin-Darby canine kidney cell culture derived influenza A\/H5N1 vaccine: a phase I trial in Taiwan","volume":"46","author":"Pan","year":"2013","journal-title":"J Microbiol Immunol Infect"},{"issue":"4","key":"10.1016\/j.jmii.2019.03.009_bib15","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1128\/CVI.00368-08","article-title":"Qualification of the hemagglutination inhibition assay in support of pandemic influenza vaccine licensure","volume":"16","author":"Noah","year":"2009","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.jmii.2019.03.009_bib16","author":"World Health Organization"},{"issue":"1\u20132","key":"10.1016\/j.jmii.2019.03.009_bib17","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.virusres.2004.02.029","article-title":"Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use","volume":"103","author":"Hehme","year":"2004","journal-title":"Virus Res"},{"issue":"4","key":"10.1016\/j.jmii.2019.03.009_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000049","article-title":"Antigenic fingerprinting of H5N1 avian influenza using convalescent sera and monoclonal antibodies reveals potential vaccine and diagnostic targets","volume":"6","author":"Khurana","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.jmii.2019.03.009_bib19","series-title":"Guideline on dossier structure and content for pandemic influenza vaccine marketing authorisation application (revision)","author":"European Medicines Agency (EMA)","year":"2008"},{"key":"10.1016\/j.jmii.2019.03.009_bib20","series-title":"Influenza virus vaccine, H5N1 (for National Stockpile)","author":"Food and Drug Administration (FDA) of the United States of America","year":"2007"},{"issue":"13","key":"10.1016\/j.jmii.2019.03.009_bib21","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJMoa055778","article-title":"Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine","volume":"354","author":"Treanor","year":"2006","journal-title":"N Engl J Med"},{"issue":"49","key":"10.1016\/j.jmii.2019.03.009_bib22","doi-asserted-by":"crossref","first-page":"6918","DOI":"10.1016\/j.vaccine.2009.08.110","article-title":"Humoral and cellular immune responses to split-virion H5N1 influenza vaccine in young and elderly adults","volume":"27","author":"Leroux-Roels","year":"2009","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.jmii.2019.03.009_bib23","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.vaccine.2009.10.019","article-title":"Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1\/2 clinical trial","volume":"28","author":"Keitel","year":"2010","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.jmii.2019.03.009_bib24","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1086\/605608","article-title":"A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses","volume":"200","author":"Ehrlich","year":"2009","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.jmii.2019.03.009_bib25","doi-asserted-by":"crossref","first-page":"178","DOI":"10.4161\/hv.6.2.9899","article-title":"Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses","volume":"6","author":"Pandey","year":"2010","journal-title":"Hum Vaccine"},{"key":"10.1016\/j.jmii.2019.03.009_bib26","series-title":"Pandemic influenza vaccine (H5N1) (whole virion, inactivated, adsorbed)","author":"(EMA) EMA. Daronrix","year":"2007"},{"issue":"47","key":"10.1016\/j.jmii.2019.03.009_bib27","doi-asserted-by":"crossref","first-page":"6642","DOI":"10.1016\/j.vaccine.2009.03.015","article-title":"Safety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A\/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults","volume":"27","author":"Keitel","year":"2009","journal-title":"Vaccine"},{"issue":"45","key":"10.1016\/j.jmii.2019.03.009_bib28","doi-asserted-by":"crossref","first-page":"6078","DOI":"10.1016\/j.vaccine.2015.09.022","article-title":"A clinical phase I study of an EB66 cell-derived H5N1 pandemic vaccine adjuvanted with AS03","volume":"33","author":"Naruse","year":"2015","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.jmii.2019.03.009_bib29","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/infdis\/jiv091","article-title":"Immunogenicity and safety of an EB66 cell-culture-derived influenza a\/Indonesia\/5\/2005(H5N1) AS03-adjuvanted vaccine: a phase 1 randomized trial","volume":"212","author":"Schuind","year":"2015","journal-title":"J Infect Dis"},{"issue":"8","key":"10.1016\/j.jmii.2019.03.009_bib30","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1517\/14712590903066695","article-title":"Prepandemic H5N1 influenza vaccine adjuvanted with AS03: a review of the pre-clinical and clinical data","volume":"9","author":"Leroux-Roels","year":"2009","journal-title":"Expert Opin Biol Ther"},{"issue":"9587","key":"10.1016\/j.jmii.2019.03.009_bib31","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/S0140-6736(07)61297-5","article-title":"Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial","volume":"370","author":"Leroux-Roels","year":"2007","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.jmii.2019.03.009_bib32","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/S1473-3099(09)70153-7","article-title":"Immunogenicity and adverse events of avian influenza A H5N1 vaccine in healthy adults: multiple-treatments meta-analysis","volume":"9","author":"Manzoli","year":"2009","journal-title":"Lancet Infect Dis"},{"issue":"1\u20132","key":"10.1016\/j.jmii.2019.03.009_bib33","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.virusres.2004.02.019","article-title":"Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A\/Duck\/Singapore\/97 vaccine","volume":"103","author":"Stephenson","year":"2004","journal-title":"Virus Res"},{"issue":"24","key":"10.1016\/j.jmii.2019.03.009_bib34","doi-asserted-by":"crossref","first-page":"11825","DOI":"10.1128\/JVI.74.24.11825-11831.2000","article-title":"Sialic acid species as a determinant of the host range of influenza A viruses","volume":"74","author":"Suzuki","year":"2000","journal-title":"J Virol"},{"issue":"33","key":"10.1016\/j.jmii.2019.03.009_bib35","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1016\/j.vaccine.2017.06.044","article-title":"Safety and immunogenicity of an inactivated cell culture-derived H7N9 influenza vaccine in healthy adults: a phase I\/II, prospective, randomized, open-label trial","volume":"35","author":"Wu","year":"2017","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.jmii.2019.03.009_bib36","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1093\/infdis\/jiu123","article-title":"A live attenuated influenza A(H5N1) vaccine induces long-term immunity in the absence of a primary antibody response","volume":"209","author":"Talaat","year":"2014","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.jmii.2019.03.009_bib37","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.vaccine.2014.11.018","article-title":"Immunogenicity of heterologous H5N1 influenza booster vaccination 6 or 18 months after primary vaccination in adults: a randomized controlled clinical trial","volume":"33","author":"Langley","year":"2015","journal-title":"Vaccine"}],"container-title":["Journal of Microbiology, Immunology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118218301762?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118218301762?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T13:24:12Z","timestamp":1761657852000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1684118218301762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S1684118218301762"],"URL":"https:\/\/doi.org\/10.1016\/j.jmii.2019.03.009","relation":{},"ISSN":["1684-1182"],"issn-type":[{"value":"1684-1182","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The safety and immunogenicity of a cell-derived adjuvanted H5N1 vaccine \u2013 A phase I randomized clinical trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Microbiology, Immunology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmii.2019.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}